Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
about
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusTeneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetesBeneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metforminSitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapyClinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combinationFixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes.Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism.Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.Effect of the addition of sitagliptin and miglitol on insulin-treated type 2 diabetes.Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus.Sitagliptin/Metformin (janumet) as combination therapy in the treatment of type-2 diabetes mellitusNovel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.Incretin-based therapies in type 2 diabetes mellitus.Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes.Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents.A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment.History and diagnostic significance of C-peptide.Metformin therapy and clinical uses.Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance.Linagliptin as add-on therapy to insulin for patients with type 2 diabetesTreatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion.DPP-4 inhibitors in clinical practice.Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin.Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus.Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence.Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.Choosing a gliptin.Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology.What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus?Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus.Sitagliptin-induced hemolysis.C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor TherapyEffect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.
P2860
Q24235718-6A0E8EEC-E3EA-4180-82A6-52031D124A12Q24240522-1329AEB0-B8FB-4329-AB02-8EF050B89EBEQ24628948-2AB27892-8F12-411D-8AB1-51D621C30F8EQ24642412-D364E896-3171-4BF4-8A1A-13393669ACF8Q26739888-506CBF25-E92E-41A8-B994-549EBD0C6736Q27026211-C5921CB7-85EA-4013-ABEC-CF03245ADE4EQ34620693-B20056CF-0B78-43FD-8D88-FD180D3EE65DQ34990233-A12302C8-EE8C-41AC-99BE-BDB4D313F617Q35496591-FA1B7DFC-EEE7-44F6-990F-055E85C14D1BQ35928257-041655FA-65EC-47F3-9B9A-27005933AEFFQ36202964-7408FC00-1985-40CA-A9B0-149A887043D8Q36428062-C1BAF05A-244B-4C07-9B01-4309FA68316DQ36428096-0D99AE6A-19AC-4BA1-A23A-6D5A56625984Q36523423-E8FBC655-1782-4B7B-A232-020CB15CAB8AQ36812821-BE2092F2-E5BB-4676-8AF5-C02B9B71FDA4Q36945112-C9CA7C38-6172-43DA-9739-118C00DDC0CBQ36964866-DE933641-A199-4366-BBB9-34888CA55216Q37022837-2A55FDD6-9F69-4C97-B535-0550C4995D57Q37161925-24B80710-EFCC-4808-8232-8387779E308DQ37164446-DB92FB1B-82E2-4AF1-A41C-8628186C109CQ37176063-1808AB3F-49CB-4C40-A55B-F48210877BF9Q37262966-0748092C-D1FA-4A3D-AB77-F3548CA0574EQ37279362-CD8D48A9-F8EC-40AE-970D-75AEDAC16719Q37281205-F0D95C9A-43EB-44C2-B379-F75A723CEFA6Q37404353-6FF10313-1C5E-4D0A-B1D8-3AC0B3365C91Q37638984-48033B0A-143D-4EE8-B8F6-16A96182136CQ37779779-71906C20-AAE3-43BD-BB1A-149927370FC9Q37841554-BAAE07E3-060C-4CD1-AAE9-10A43EB6BAB4Q37857686-FF747FB7-348A-490E-A531-C1925B348A76Q37857691-5582A8C7-FD18-4ACE-9908-E5030476B50AQ37900690-1E349F7B-F6A2-42DC-B611-4E19187F6CB5Q37941683-9EE7B492-A155-44BF-9A90-77F863D991FDQ37949599-1BB46DFE-0F16-4164-9626-B353C0652983Q38062881-D8B74577-001F-4005-93D1-06EA883E69A1Q38137389-64CF2FFC-CCFD-44F7-8FED-BD7AAA71E44CQ41863397-675E3E81-F7A2-430B-9D3A-75CB0FA1FE6AQ41895681-463B57B5-1E31-4510-B89E-D17ED1A5690AQ42368200-BC00BECD-58FB-4FB5-8F56-8A0741CDA315Q42436026-8D36FCD4-F082-452E-B7AB-A4074EE66825Q42440190-50142158-E314-44AE-B88A-FBD5E2541B6B
P2860
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Effect of adding sitagliptin, ...... patients with type 2 diabetes.
@en
Effect of adding sitagliptin, ...... patients with type 2 diabetes.
@nl
type
label
Effect of adding sitagliptin, ...... patients with type 2 diabetes.
@en
Effect of adding sitagliptin, ...... patients with type 2 diabetes.
@nl
prefLabel
Effect of adding sitagliptin, ...... patients with type 2 diabetes.
@en
Effect of adding sitagliptin, ...... patients with type 2 diabetes.
@nl
P2093
P2860
P1476
Effect of adding sitagliptin, ...... patients with type 2 diabetes
@en
P2093
P2860
P304
P356
10.1111/J.1463-1326.2006.00691.X
P577
2007-03-01T00:00:00Z